Page last updated: 2024-10-22

anastrozole and Pituitary Neoplasms

anastrozole has been researched along with Pituitary Neoplasms in 2 studies

Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.

Research Excerpts

ExcerptRelevanceReference
"Most prolactinomas respond rapidly to low doses of dopamine agonists."1.31The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. ( Freed, DJ; Gillam, MP; Middler, S; Molitch, ME, 2002)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Ceccato, F1
Lizzul, L1
Voltan, G1
Barbot, M1
Scaroni, C1
Gillam, MP1
Middler, S1
Freed, DJ1
Molitch, ME1

Other Studies

2 other studies available for anastrozole and Pituitary Neoplasms

ArticleYear
Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients.
    Pituitary, 2021, Volume: 24, Issue:6

    Topics: Anastrozole; Cabergoline; Dopamine Agonists; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactin

2021
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
    The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:10

    Topics: Adult; Anastrozole; Aromatase Inhibitors; Bromocriptine; Cabergoline; Dopamine Agonists; Enzyme Inhi

2002